Idenix Pharmaceuticals Appoints Charles Rowland to Its Board of Directors
June 10 2013 - 8:00AM
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical
company engaged in the discovery and development of drugs for the
treatment of human viral diseases, today announced that it has
appointed Charles Rowland to its Board of Directors. Mr. Rowland is
Vice President and Chief Financial Officer of ViroPharma
Incorporated. His appointment to Idenix's Board is effective
immediately.
"Charlie brings valued financial expertise and background, with
strong experience implementing mid- and long-term strategic
planning at innovative biopharma companies," said Ron Renaud,
President and Chief Executive Officer of Idenix. "We are pleased to
welcome Charlie to the Idenix Board at an important time for the
Company as it continues to advance all-oral combination therapies
for HCV, including a lead program in Phase II and earlier
candidates approaching the clinic."
Mr. Rowland has more than 28 years of diversified experience
across a broad field of financial areas and accounting, including
financial reporting, tax, treasury, and strategic financial
planning. Prior to joining ViroPharma, he was executive vice
president and chief financial officer at Endo Pharmaceuticals and
served for a period as co-interim chief executive officer.
Previously, Mr. Rowland was senior vice president, chief
financial officer for Biovail Pharmacueticals. He also
previously held positions of increasing responsibility at Breakaway
Technologies, Pharmacia, Novartis and Bristol-Myers Squibb Company.
Mr. Rowland holds a Bachelors of Science in accounting from
St. Joseph's University, and a Master of Business Administration
degree from the Rutgers University.
ABOUT IDENIX
Idenix Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts, is a biopharmaceutical Company engaged in the
discovery and development of drugs for the treatment of human viral
diseases. Idenix's current focus is on the treatment of
patients with hepatitis C virus (HCV) infection. For further
information about Idenix, please refer to www.idenix.com.
CONTACT: Idenix Pharmaceuticals Contact:
Teri Dahlman, (617) 995-9807
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024